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Abstract
Background: Although bone marrow metastases can be found commonly in some malignant tumors,
diagnosing a nonhematologic malignancy from marrow is not a usual event.
Methods: To underscore the value of bone marrow aspiration and biopsy as a short cut in establishing a
diagnosis for disseminated tumors, we reviewed 19 patients with nonhematologic malignancies who
initially had diagnosis from bone marrow.
Results: The main indications for bone marrow examination were microangiopathic hemolytic anemia
(MAHA), leukoerythroblastosis (LEB) and unexplained cytopenias. Bone marrow aspiration was not
diagnostic due to dry tap or inadequate material in 6 cases. Biopsy results were parallel to the cytological
ones in all cases except one; however a meticulous second examination of the biopsy confirmed the
cytologic diagnosis in this patient too. The most common histologic subtype was adenocarcinoma, and
after all the clinical and laboratory evaluations, the primary focus was disclosed definitively in ten patients
(5 stomach, 3 prostate, 1 lung, 1 muscle) and probably in four patients (3 gastrointestinal tract, 1 lung). All
work up failed in five patients and these cases were classified as tumor of unknown origin (TUO).
Conclusion: Our series showed that anemia, thrombocytopenia, elevated red cell distribution width
(RDW) and hypoproteinemia formed a uniform tetrad in patients with disseminated tumors that were
diagnosed via bone marrow examination. The prognosis of patients was very poor and survivals were only
a few days or weeks (except for 4 patients whose survivals were longer). We concluded that MAHA, LEB
and unexplained cytopenias are strong indicators of the necessity of bone marrow examination. Because
of the very short survival of many patients, all investigational procedures should be judged in view of their
rationality, and should be focused on treatable primary tumors.
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Background
Diagnosis and management of many hematologic dis-
eases depends on examination of the bone marrow, which
usually involves two separate specimens: a cytologic and a
histologic preparation. While cytologic preparation of
bone marrow, obtained by aspiration, allows excellent
visualization of cell morphology, the second one, usually
obtained with a Jamshidi needle, allows optimal evalua-
tion of cellularity, fibrosis or infiltrative disease. In addi-
tion to hematologic malignancies, bone marrow
examination has been increasingly useful in documenting
metastatic involvement of tumors. During the past four
decades, prospective evaluation of bone marrow aspirates
and biopsy specimens has come into widespread use for
accurate staging of many malignant diseases. Recognition
of metastasis in random biopsies presents challenges to
hematologists and pathologists when diagnosing the pri-
mary focus [1,2]
Although marrow metastases can be found commonly in
some tumors, especially when newer sensitive methods
are applied for the detection of tumor cells, diagnosing a
nonhematologic malignancy from marrow is a rare event.
We reviewed 19 patients with nonhematologic malignan-
cies who were diagnosed initially from bone marrow, to
underscore the value of bone marrow aspiration and
biopsy as a short cut in establishing a diagnosis for dis-
seminated tumors. Additionally we reported the details of
the management and survival of the cases to offer a prac-
tical suggestion about work up of these patients to find a
primary focus.
Methods
This study is based on our retrospective analysis of 19
patients with solid tumors whose diagnoses were made
from bone marrow seen at the Department of Hematol-
ogy, Uludag University Medical Faculty, over a period of 9
years. Patients with non-Hodgkin's lymphomas and
Hodgkin's diseases were not included in this study and
patients with known neoplastic disease were also
excluded.
The standard technique was employed in obtaining the
samples from posterior iliac crest using a Jamshidi needle
(Regular/Adult, 11-gauge). All of the trephine biopsies
were performed unilaterally, because clinically none of
the diseases that focally involve the bone marrow were
included in the differential diagnosis prior to the biopsy
procedure. Length of the biopsy cores ranged between 1.2
cm and 2.2 cm (mean 1.7 cm). Trephine biopsies were
fixed in 10% neutral buffered formaline for at least 24
hours, and then decalcified overnight in a decalcifying
solution which is a mixture of 8% HCl and 10% formic
acid at equal amounts of volume. Following the auto-
mated tissue processing, biopsies were embedded in
parafin blocks, and 0.3 micrometer sections were cut. In
some cases the sternum was sampled using a Rosenthal
needle for aspiration. Touch preparations were done if the
aspiration resulted in a "dry tap" or if aspiration material
was considered to be technically inadequate for evalua-
tion, or if it was hemodilute. Bone marrow aspiration,
touch preparations and peripheral blood smears which
were obtained at the same time by biopsy were stained by
May Grunwald-Giemsa. Hematoxylene-eosin, Giemsa
and reticulin stains were routinely performed in biopsy
sections. If the nonhematologic properties of the tumor
could be identified with routine stains, and if the primary
of the metastatic tumor could easily be diagnosed mor-
phologically with routine hematoxylene-eosin stains, as
in the cases of signet ring cell carcinoma; no immunohis-
tochemical study was held. The pathologist's approach to
definitive diagnosis of the patient with metastasis of
unknown primary effectively followed a few sequential
steps: First of all we tried to determine the cell line of dif-
ferentiation e.g. carcinoma, lymphoma, melanoma, sar-
coma, or germ cell, with the help of morphological
findings and if needed, immunohistochemical stains. Our
panel of antibodies contained pancytokeratin, HMB45,
Leukocyte Common Antigen (LCA), Vimentin and Pla-
cental Alkalen Phosphatase (PLAP). If it was an epithelial
tumor we tried to determine the cytokeratin (CK) type or
types of distribution in the tumor cells, since some subsets
of cytokeratins are uniqe to certain tumor types. Our
panel contained AE1/AE3, CAM5.2, CK7, CK20, and 34
beta E12. In our further studies we tried to determine if
there was expression of supplemental antigens of epithe-
lial or germ cell derivation, that was Carcinoembryonic
Antigen (CEA), Epithelial membrane Antigen (EMA) or
PLAP. Last step was to determine if there was expression
of cell-specific structures or receptors that are unique iden-
tifiers of cell types, for example neuroendocrine granules,
peptide hormones, thyroglobulin, Prostate Specific Anti-
gen (PSA), Gross Cystic Disease Fluid Protein (GCDFP) or
Thyroid Transcription Factor-1 (TTF-1). Our panel of anti-
bodies contained Synaptophysin, Chromogranin, Neuron
Specific Enolase (NSE), Thyroglobuline, PSA, GCDFP,
and TTF-1. Cases with sarcomatous properties were
immunostained with Desmin, Smooth Muscle Actin,
S100, Vimentin and Myoglobulin. After the confirmation
of original peripheral blood and bone marrow cytological
findings and histopathological diagnoses by a senior
hematologist and an expert pathologist the patient charts
were reviewed. Cases with a history of malignancy at the
time of presentation were excluded.
Patient characteristics were recorded in each case, includ-
ing: presenting symptoms, onset of symptoms, physical
examination findings, peripheral blood counts, periph-
eral blood morphology, diagnostic evaluation, manage-
ment, and survival.BMC Cancer 2005, 5:144 http://www.biomedcentral.com/1471-2407/5/144
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Table 1: Clinical and cytopathological characteristics of patients
No Age/sex Presenting symptoms/
Onset of symptoms/
Presence of 
constitutional 
symptoms
Performance status*/
Physical findings
Cytological examination 
of peripheral blood
Cytological examination 
of bone marrow
Pathological 
examination of bone 
marrow
1 50/M Back and chest pain/3 
weeks/WL, F, NS
3/Pallor, subicterus MAHA, LEB Dilute, not optimal, not 
diagnostic
Adenocarcinoma with 
signet ring cell features 
(Suggestion: primary 
focus should be 
searched in GI tract)
2 40/M Abdominal pain, failure 
to passage gas and stool 
by rectum, 
hematemesis/2 weeks/
NS
3/Ecchymoses, 
tenderness in 
epigastrium and lower-
right quadrant
MAHA, LEB Dilute, not optimal, not 
diagnostic
Adenocarcinoma
3 41/F Lumbar and extremity 
pain, lack of appetite, 
nausea/4 weeks/WL, F
3/Pain with deep 
palpation of whole 
abdomen
LEB, MAHA Dilute, not optimal, not 
diagnostic
Adenocarcinoma
4 48/F Lack of appetite, fatigue, 
nausea, vomiting, fever/
2 months/F, WL
3/A few ecchymoses LEB Dry tap; touch 
preparation is not 
optimal for evaluation
Indifferentiated 
carcinoma (only CK 
positive strongly)
5 49/F Dyspepsia, weakness/1 
month/F
3/Pallor, multiple 
ecchymoses, axillary 
single microLAP
LEB Dense foreign cell 
infiltration forming 
groups 
(adenocarcinoma)
Adenocarcinoma
6 71/M Lumbar and leg pain, 
somnolence/20 days/-
4/Pallor, impaired 
consciousness, 
dysorientation, 
dyscooperation, 
agitation
LEB Dry tap; imprint: highly 
dense atypical 
somewhat large round 
or oval cells infiltration 
in clusters
Atypical epithelial cells 
in clusters (round cells 
infiltration) (Suggestion: 
Primary focus should be 
investigated in lungs)
7 63/M Cough, dysphagia, 
abdominal swelling, 
weakness, prominent 
loss in weight/WL, F, 
NS/1 month
2/Scleral icterus, 5 cm 
hepatomegaly, melana in 
rectal digital palpation
LEB Epithelioid cells in solid 
clusters (small cell 
carcinoma infiltration)
Small cell carcinoma
8 57/F Back, lumbar and leg 
pain, weakness, lack of 
appetite/3 months/WL
3/Scleral icter, left 
axillary 2 cm LAP
MAHA, LEB Infiltration with signet 
ring cells
Metastatic carcinoma 
(signet ring cell 
adenocarcinoma)
9 45/M Lumbar and leg pain, 
prominent loss in 
weight, generalized 
body pain/2 months/WL
3/Pallor; LEB Infiltration with atypical 
large epithelioid cells
Metastatic carcinoma 
(Suggestion: Primary 
tumor should be 
investigated in prostate)
10 25/F Weakness, hip pain/6 
months/ WL
2/Pallor, right inguinal 2 
cm LAP, 1 cm 
hepatomegaly, 2 cm 
splenomegaly
Rare blastic cells Infiltration with blastic 
cells with vacuolated 
cytoplasm (MPO 
negative; flow: B and T 
cell markers negative)
Higly dense atypical 
cells in alveolar 
structure-actin, desmin 
and vimentin positive, 
LCA and CK negative-
(metastatic alveolar 
rhabdomyosarcoma)
11 35/M Nausea, vomiting, 
prominent loss of 
weight, fatigue (alcohol, 
hashish and heroin 
dependence)/1 month/
F, WL
4/Pallor, cachexia MAHA Adenocarcinoma cell 
forming groups
Metastatic 
adenocarcinoma
12 83/F Prominent loss in 
weight, nausea, 
vomiting; backpain/6 
months/WL
3/Pallor; multipl 
ecchymoses
MAHA, LEB Infiltration with signet 
ring cell carcinoma cells
Metastatic 
adenocarcinoma (signet 
ring cell carcinoma 
metastasis)
13 61/F Headache, sore throat, 
abdominal pain, 
constipation, nausea, 
vomiting (hematemesis 
and melana history), 
weakness/2 months/-
2/Pallor and scleral 
icterus, pain with 
palpation of right 
hypochondrium
LEB Dry tap in first 2 
attempts and very dilute 
without particle in 3rd 
attempt. No atypical 
cells; imprint: technically 
inadequate
Metastatic carcinoma 
(CK positive atypical 
epithelioid cell 
infiltration, some of 
them in signet ring cell 
shape)BMC Cancer 2005, 5:144 http://www.biomedcentral.com/1471-2407/5/144
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Results
Between 1995 and 2004, bone marrow metastasis was
diagnosed in 19 samples among 5420 bone marrow aspi-
rations and 856 bone marrow trephine biopsies. The ages
of the patients were between 25 and 83 years (median age:
56), eight of them were female.
The main indications for bone marrow examination were
microangiopathic hemolytic anemia (MAHA), leukoery-
htroblastosis (LEB) and peripheral cytopenias. Constitu-
tional symptoms and pain were the most prominent
presenting symptoms of the patients. Clinical findings
were highly variable according to the underlying disease.
In the laboratory, the most common findings were ane-
mia and thrombocytopenia, which were found in all
patients. White blood cell counts (WBC) were between
3.3 × 109/l and 17.1 × 109/l (median: 8.1 × 109/l), red cell
distribution width (RDW) was increased in all cases,
whereas mean corpuscular volume (MCV), mean corpus-
cular hemoglobin (MCH), reticulocyte percentage (RET)
and erythrocyte sedimentation rate (ESR) were highly var-
iable. Coagulation tests were carried out in 17 patients
and in 8 of them at least one anomaly was detected at
presentation; additionally, in two patients who had nor-
mal test results initially subsequent tests were found
abnormal. All patients had hypoproteinemia; the second
most common anomaly was elevated serum lactate dehy-
drogenase (LDH) level, which was found normal in only
one patient (patient # 13) in biochemical analyses; some
hepatic and renal parameters were abnormal in some
patients but none of them was a constant finding.
In 6 cases bone marrow aspiration was not diagnostic due
to dry tap or inadequate material. Histopathological
examinations confirmed the nonlymphohematopoietic
cell infiltration in first evaluation except one (patient #
15). However, a meticulous second evaluation of biopsy
confirmed the cytologic diagnosis in this patient too. The
most common histologic subtype was adenocarcinoma.
After the all clinical and laboratory evaluations, the pri-
mary focus was disclosed in ten patients definitively (5
stomach, 3 prostate, 1 lung, 1 muscle) and in four patients
probably (3 gastrointestinal tract, 1 lung). In five patients
all work up failed and these cases were classified as tumor
of unknown origin (TUO).
14 75/M Multiple ecchymoses on 
body and on 
extremities, purpura on 
lower extremities; 
hematuria/2 days/-
1/Ecchymoses and 
purpura; 1.5 cm 
supraclavicular LAP
Only minimal shift to 
left; no erythroblast or 
poikilocytosis
Non-hematopoetic cell 
infiltration forming 
groups and some with 
mucineous character
Metastatic 
adenocarcinoma (CK+ 
cells forming glandular 
and tubular structures
15 73/M Confusion, adynamia/20 
days/WL
4/Hypotension, 
hypothermia, 
dehydration, scleral 
icterus, pallor, cachexia, 
2 cm hepatomegaly
Slight shift to left, toxic 
granulation, slight 
poikilocytosis, no 
erythroblast, no 
fragmentation
Dilute and not optimal 
but there are 
nonhematopoietic cells 
in small groups like 
adenocarcinoma cells
Nondiagnostic in first 
report but 
adenocarcinoma 
metastasis reported 
after meticulous 
examination of new 
further sections of 
blocks
16 75/F Dyspnea, abdominal 
swelling/20 days/-
4/Rales bilaterally, 2 cm 
hepatomegaly, pretibial 
edema, petechia in 
lower extremities
LEB, no poikilositosis or 
fragmentation
Atypical non-
haematopoetic cells 
(adenocarcinoma 
metastasis)
ND
17 68/M Weakness, lack of 
appetite, prominent loss 
of weight, lumbar pain/3 
months/WL
1/Enlargement and 
nodulation in prostate 
in digital examination
LEB, slight 
poikilocytosis, no 
fragmentation
Infiltration with 
adenocarcinoma cells 
showing acinar and 
tubular structures
Metastatic carcinoma 
compatible with 
prostate carcinoma 
(PSA +)
18 56/M Pain in hips and legs, 
weakness/2 months/F, 
WL, SN
2/Pallor, cachexia, 
multiple microLAPs in 
servical, axillary and 
inguinal regions, a few 
petechiae and 
eccyhymoses
LEB, MAHA Infiltration with atypical 
epithelioid cells forming 
papillar and acinar 
structures 
(adenocarcinoma 
metastasis)
CK + PAS- 
adenocarcinoma 
metastasis (Suggestion: 
Primary focus should be 
investigated in prostate)
19 45/M Neck and hip pain, 
abdominal pain, 
weakness/ 1 month/WL
3/restriction in physical 
activity
LEB, MAHA Infiltration with 
adenocarcinoma cells
Metastatic 
adenocarcinoma; CK+ 
epithelioid cells, some 
of them mucinous and 
in shape of signet cell 
(Suggestion: Primary 
focus should be 
investigated in stomach)
*According to WHO/ECOG; WL: weight loss; F: fever; NS: night sweats; LAP: lymphadenopathy; MAHA: microangiopathic hemolytic anemia; LEB: 
leukoerythroblastosis; MPO: myeloperoxidase; CK: Cytokeratin LCA: leukocyte common antigen; ND: not done
Table 1: Clinical and cytopathological characteristics of patients (Continued)BMC Cancer 2005, 5:144 http://www.biomedcentral.com/1471-2407/5/144
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Table 2: Evaluation, clinical course and survival of patients
Evaluation for primary focus Final decision for
primary focus
Clinical course/Management Survival
1 Chest XR, abdominopelvic USG and transrectal USG: 
N; CEA and CA15.3 are high slightly and Ca19.9 is 
high more than 10 folds, among CEA, α FTP, PAP, 
CA-125, CA19.9, CA15.3
GI tractus General condition deteriorated rapidly; stupor and 
coma developed/Supportive care; 2 courses of TPE
6 days
2 Chest XR, abdominopelvic USG and CT: N; 
gastroscopy: malign ulcus
Stomach DIC, subdural hematoma developed/Multiple 
erythrocyte, platelet and plasma transfusions; 2 
courses of TPE
11 days
3 Abdominopelvic USG and CT: thickness on the 
antrum wall, gastrohepatic and portahepatic 
microLAPs; only α-FTP is in normal limits, among the 
CEA, α-FTP, CA 125, CA15.5; CA19.9 is high more 
than 10 folds; gastroscopy: infiltration in corpus and 
antrum (linitis plastica)
Stomach DIC diagnosed at admission. Hematemesis and 
epistaxis developed later/Despite full transfusion 
support; died due to intracerebral bleeding
20 days
4 Chest XR, mammography: N; abdominopelvic USG 
and CT: N except minimal free pelvic fluid; upper GI 
tract endoscopy: unremarkable
TUO Fever resisted despite AB; general condition 
deteriorated gradually, generalized seizures 
developed without abnormal cranial CT finding; 
hypoxemia developed due to secretions/Supportive 
care only
12 days
5 Chest XR: N; abdominopelvic CT: not optimal; 
suspected thickness on the stomach wall, suspected 
metastatic lesions in columna vertabralis; upper GI 
tract endoscopy: malign ulcus in cardia; CA125 is high 
slightly and CA-19-9 is high approximately 6 times, 
among CEA, α-FTP, Ca 125, CA 19-9, CA 15-3
Stomach AB resistant fever (FUO) and GI tract bleeding 
developed later/Despite full transfusion support her 
general condition deteriorated rapidly. Died in 
MODS picture
37 days
6 Cranial CT: N; thorax, abdomen and pelvis MR: 
multiple mediastinal LAPs in conglemeration with 
suspected parenchimal infiltration, benign prostate 
hyperthrophy; lumbar MR: multiple pathologic signal 
in backbone and degenerative alterations; Skeleton 
scintigraphy: multiple thoracal and lumbar uptake 
(degeneration, metastasis, trauma?)
Lung? His consciousness impaired progressively; refractory 
fever and hypotension developed
5 days
7 Thorax, abdominal CT: subcarinal LAPs, a mass in 
right hilus, eosophagial compression, pulmonary 
artery and pericardium invasion, a hipodens lesion in 
1 cm diameter in liver (USG in terminal period: 
multiple lesions compatible with metastasis); 
bronchoscopy: inoperable bronchial carcinoma; 
biopsy: small cell carcinoma); upper GI tract 
endoscopy: N. CEA, α-FTP, PSA, freePSA, CA125, 
CA 19.9 all: N
Lung Pneumonia and atrial fibrillation developed/A course 
of CT (Etoposide+Cisplatine) was given. Died duo to 
CHF
47 days
8 Axillary node FNAB: benign; cranial MR: compatible 
with bone metastasis and leptomeningeal 
carcinomatosis; thorax CT: only bone metastasis; 
abdominopelvic CT: 3 mm hipodens lesion in liver 
(metastasis?), backbone metastasis; transvaginal USG: 
N; bone scintigraphy: multiple metastasis; 
mammography: N; whole spine MR: generalized 
sclerotic and lytic lesions; upper GI tract endoscopy: 
erythemateous gastritis; only CA 125 is high 2 folds, 
among CEA, α-FTP, CA 125, CA 19-9, CA15-3, 
BHCG
TUO Performance status deteriorated gradually. GI tract 
bleeding developed/She refused colonoscopy and 
other supportive therapies and was discharged in 
very bad condition
38+ days
9 Chest XR: N; transrectal USG: prostate carcinoma?; 
prostate biopsy: adenocarcinoma; skelatal XR survey: 
multiple sclerotic metastasis and compression 
fracture in L3; bone scintigraphy: generalized 
metastatic involvement; tumor markers: PSA and free 
PSA are very high
Prostate After his work up bisphosphonates therapy was 
initiated and was fallowed as outpatient; cranial 
metastasis developed later; despite progressive 
complaints he refused admission
7+ months
10 Abdominopelvic CT: a solid mass in the pelvis 
originated probably right gluteal muscle and 
homogeneous hepatosplenomegaly; biopsy from the 
mass: rhabdomyosarcoma; skelatal XR survey: lytic 
lesions in only pelvic bones and proximal femur; bone 
scintigraphy: pathologic uptake in bilateral knee, 
pelvic area and, 5. and 7. ribs
Muscle VAC/IE (Vincristine, Adriamycine, 
Cyclophosphomide, Ifosfamide, etoposide) therapy 
resulted in partial response; died because of 
progression later
7 monthsBMC Cancer 2005, 5:144 http://www.biomedcentral.com/1471-2407/5/144
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The prognosis of patients was very poor and survivals were
only a few days or weeks except for 4 patients whose sur-
vivals were longer (patients # 9, 10, 17, 18). To avoid
missing the individual features, detailed tables were pre-
pared: Clinical and cytopathologic characteristics are
shown in Table 1, clinical courses and survivals are shown
in Table 2, and some hematological and biochemical fea-
tures are shown in Table 3.
Discussion
Although bone marrow metastases are frequently encoun-
tered in patients with disseminated solid tumors, it is not
a common event as a presenting sign. It stems from two
possible reasons: i) in general, bone marrow is seldom the
sole site of systemic involvement by malignant disease
and ii) bone marrow examination in evaluating patients
with suspected malignancy has a limited value unless sup-
ported by some other clinical finding, such as a leuko-
erythroblastic reaction [1,3,4]. Although there are a
number of correlates that may be useful, there is no single
specific finding that is an indicator of marrow infiltration.
Furthermore, in most patients with neoplastic infiltration
of the marrow, the peripheral blood findings do not differ
significantly from those without marrow involvement.
Our series showed that MAHA, LEB and unexplained cyto-
penias are strong indicators of the necessity of bone mar-
row examination. When we reviewed routine hematologic
and biochemical parameters we found that only four were
present in all patients: anemia, thrombocytopenia, ele-
vated RDW and hypoproteinemia. However, our results
11 Chest XR: N; abdominopelvic US: N except 
homogen minimal hepatomegaly
GI system? His general condition deteriorated rapidly; GI tract 
bleeding and subdural hematoma developed, Died 
because of herniation/Supportive care only
10 days
12 Abdominopelvic CT: normal except suspected 
rigidity in stomach wall; gastroscopy: malign ulcus in 
junction of corpus and fundus; biopsy: 
Adenocarcinoma; Mammography: N; Backbone XR: 
loss of height in Th11 and Th12
Stomach One course 5FU+FA was given; died as out patient 1 month
13 Nasopharynx biopsy: N; pleural fluid cytology: 
negative, biopsy: nonspecific chronic pleuritis; 
mammography:N; bone scintigraphy: multiple uptake; 
colonoscopy: N; gastroscopy: N; CEA and CA15.3: 
N, CA19.9 and CA125: very high
GI system Transfusion support. Lost to follow up 45+ days
14 Chest XR and abdominopelvic USG: N TUO Nothing. Out of follow in 2nd week 14 days
15 Chest XR: nondiagnostic; CEA, α-FTP, PSA, free 
PSA, CA15.3, Ca19.9, Ca125 all: N
TUO Despite vigorous transfusion support and antibiotics 
his vital functions deteriorated progressively and died 
in MODS
4 days
16 Chest XR: nondiagnostic; previous available tests: 
thorax CT: linear atelectasis and minimal right pleural 
fluid, 1–2 cm multiple mediastinal LAPs;.abdominal 
CT: homogeneous hepatomegaly and multiple cysts 
in 1.5 cm diameter in head of pancreas
TUO She died because of hypertensive crises and CHF 
after admission
1 day
17 Pelvic and transrectal USG: Prostatic hypertrophy; 
prostate biopsy: Adenocarcinoma; thoracolumbar 
MR and bone scintigraphy: multiple bone metastasis 
in backbone
Prostate Flutamide (antiandrogen) and Goserelin asetat (LH-
LR analogue) were given. Paraparesis and paraplegia 
unresponsive to RT developed and died because of 
progressive disease and CHF
15 months
18 Neck and thorax CT: N; abdominopelvic CT: 
paraaortic 1.5 cm LAPs and heterogen prostatic 
hypertrophy, prostate biopsy: Adenocarcinoma; 
pelvis XR: multiple sclerotic lesions; bone 
scintigraphy; multiple + focuses in whole skeleton: 
PAP and PAS: very high; CEA, AFP, CA19.9: N
Prostate Gaserolin asetat+ Bikalutamid (LH-RH analogues) 
were given; (he was in a good condition when 
writing)
3+ months
19 Bone scintigraphy: multiple + uptake; gastroscopy: 
malign ulcus; biopsy: signet cell carcinoma (antrum); 
CEA, CA 19.9: very high, Ca125: high, AFP, PSA, F-
PSA:N; thoracal MR: loss of height in Th8; toraks CT: 
frosted glass appearance in lower and middle zones, 
minimal pleural effusion bilaterally; abdominopelvic 
CT:N; skelatal XR: Lumbar and pelvic sclerotic 
lesions
Stomach Supportive care and palliative RT were given; he died 
because of progressive disease
51 days
XR: direct radiography; CEA: carcinoembryonic antigen; α FTP: alpha fetoprotein; PAP: prostate specific antigen; BHCG: Beta human chorionic 
gonodotropin; USG: ultrasonography; CT: computed tomography; MR: magnetic resonance; Th: thoracal; LAP: lymphadenopathy; GI: 
gastrointestinal; DIC: disseminated intravascular coagulation; N: normal; FNAB: fine needle aspiration biopsy; TUO: tumor of unknown origin; TPE: 
therapeutic plasma exchange; AB: antibiotic; FUO: Febris of unknown origin; MODS: multiple organ deficiency syndrome; CHF: congestive hearth 
failure; RT: radiotherapy;
Table 2: Evaluation, clinical course and survival of patients (Continued)BMC Cancer 2005, 5:144 http://www.biomedcentral.com/1471-2407/5/144
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should be interpreted with caution, as the current study
was not designed to determine the predictive parameters
of marrow metastases.
LEB is the term used to describe the combination of nucle-
ated red cells (erythroblasts) and immature myeloid pre-
cursors (e.g. myelocytes and myeloblasts) in the
peripheral blood film. The mechanism of leukoerythrob-
lastic reactions is not defined. The invasion of metastatic
cancer cells may cause the early release of some cytokines,
leading to the development of a myelophthisic blood pic-
ture even before the marrow is completely replaced. This
is a possible explanation for some instances of leukoeryth-
roblastic changes in the blood of the patients with tumors
in whom marrow metastases are not documented by his-
tologic examination. Although metastatic foci can be
found in a high percentage of some carcinomas, the devel-
opment of frank LEB occurs much less frequently, so its
absence should not exclude marrow involvement. If there
is LEB in a case of suspected malignancy, bone marrow
examination should be considered. Our series confirmed
this judgment, because fifteen of the patients were pre-
sented with LEB. On the other hand despite clear bone
marrow involvement in 4 patients there were no erythroid
and myeloid precursors in their peripheral blood films
(patients # 10, 11, 14, 15). LEB was reported at different
rates in different series consisting of cancer patients with
bone marrow metastases: 10/27 [5]; 19/25 [6]; 5/63 [7];
26/73 [2]. Our relatively high LEB ratio (15/19) is not
comparable with other series because they consisted of
cancer patients who were diagnosed before bone marrow
examination. Our high LEB ratio, when considered along
with the bad outcomes, may reflect the late and advanced
cases. In recent years there is a scarcity of publications on
the association of myelophthisis with cancer. As men-
tioned by the authors in a recent report [8], early diagnosis
and more effective therapies are possible explanations for
this decrease.
MAHA or thrombotic microangiopathy (TM) describes
the association of hemolytic anemia with red cell frag-
mentation caused by microangiopathy mechanically.
Cancer related thrombotic microangiopathy (CR-TM) is a
rare and severe complication; it usually occurs in the late
or terminal stage of cancer with a short-term life-threaten-
ing prognosis [9,10]. CR-TM shares certain clinical simi-
larities with thrombotic thrombocytopenic purpura such
as neurological and renal impairment; also both are char-
acterized by circulating platelet aggregates containing
ultra large multimers of Von Willebrand factor (VWF). A
recent report showed no VWF cleaving protease deficiency
in a patient with metastatic adenocarcinoma of the colon
and microangiopathic hemolysis, who is refractory to
plasma exchange [11]. We do not have any data about
protease activity but, because of an almost identical clini-
cal picture with TTP as presentation, we started plasma
exchange immediately in patient # 1 and # 2 but therapy
failed as expected. Hemolysis, in our CR-TM patients, was
so severe that several units of transfusion per day were
required to maintain a safe hemoglobin level. Reticulocy-
tosis is expected but this finding could not be a reliable
indicator of hemolysis, as seen in our patients, because of
marrow infiltration or chronic disease. In our series, seven
out of eight MAHA patients showed LEB and six showed
abnormality in some coagulation tests suggesting dissem-
inated intravascular coagulation. When we reviewed our
eight MAHA cases there were two TUO and one prostate
carcinoma. All definitive stomach carcinomas and a prob-
able gastrointestinal carcinoma were in the MAHA group.
The survivals of our MAHA patients were between 11 and
51 days except for one (patient # 18; prostate carcinoma).
This suggests that once microangiopathic hemolysis is
seen in a patient with disseminated carcinoma, the overall
prognosis is poor, especially in stomach adenocarcinoma
presented with MAHA.
"Dry tap" is a term used to describe failure to obtain bone
marrow on attempted marrow aspirations. Extensive mar-
row fibrosis and hypercellularity have been proposed as
mechanisms to account for the inability to withdraw mar-
row by aspiration [12,13]. Because it can be attributed to
faulty technique it should only be used retrospectively
after review of the biopsy. We have two dry taps (patients
# : 4, 6). If the definition of dry tap includes cases in which
material is obtained but no, or inadequate marrow cells
found in films we have four additional cases (patients # 1,
2, 3, 13). We concluded that bone marrow biopsy is cer-
tainly indicated whenever aspiration results in an insuffi-
cient material especially in the presence of LEB, MAHA,
cytopenias and an elevated serum LDH.
Classically, marrow biopsy is unequivocally the best
method of detecting lymphomatous involvement because
in approximately one-third of cases, the aspirate is unre-
markable and the biopsy shows tumor. In solid tumors
other than those of lymphomatous origin the data in the
literature comparing the relative value of bone marrow
aspiration and biopsy in detecting marrow involvement
are not so conclusive. [2,14]. Naturally trephine biopsies
have a definitive advantage over aspirates in cases of dry
tap. Additionally histologic sections may allow classifica-
tion of the type of tumor cells, and this is of particular
value in the investigation of a patient with a malignancy
of unknown primary site. Aspirations were diagnostic in
12 patients in our series. The other attempts yielded no, or
inadequate material. Cytological diagnoses could not be
confirmed in one patient because of the patient's objec-
tion to biopsy procedure. Only in one instance was cytol-
ogy superior to biopsy in first examination (a
retrospective examination of biopsy confirmed the cyto-B
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Table 3: Hematologic parameters of peripheral blood and biochemistry of serum of patients*
No WBC
(× 109/l)
Hb
(mg/dl)
MCV 
(fl)
MCH 
(pg)
RDW PLT
(× 109/l)
RET 
(%)
ESR
(mm/1 h)
Coagulation tests Total 
Protein/
Albumin
LDH Total/
Direct 
Bil
AST ALT ALP Urea Creatinine
1 8.1 9.9 94.5 33.3 17.0 32 2.5 17 PT and FDP: high 6.3/3.4 508 3.1/1.4 49 38 525 70 0.8
2 6.8 7.0 93.2 28.7 15.6 19 3.0 20 Ne initially and all abnormal 
later
5.6/3.0 1042 1.5/0.5 157 33 365 56 1.0
3 11.6 6.4 79.7 27.0 16.1 20 1.0 36 PT aPTT and FDP: abnormal 5.0/2.1 776 2.9/1.1 67 57 587 46 0.4
4 13.1 6.8 74.1 25.2 18.4 41 0.8 78 N 5.7/2.6 1669 0.9/0.5 104 48 282 148 2.1
5 15.8 6.6 82.0 26.3 16.7 18 3.5 34 N initially but abnormal later 5.8/2.7 1016 2.4/1.1 61 11 661 84 0.8
6 10.6 10.6 73.8 24.4 15.3 12 0.2 107 N 6.2/2.8 1255 0.5/0.3 52 22 240 89 1.2
7 4.2 9.3 85.7 29.2 15.2 21 1.4 80 N 5.8/3.6 1438 1.1/0.5 78 54 155 68 1.0
8 6.5 8.1 89.3 30.9 16.5 72 4.7 44 N 5.7/2.9 880 2.3/0.9 30 17 1548 33 0.5
9 6.4 9.5 61.9 20.5 16.3 45 1.0 65 N 6.4/3.4 665 0.5/0.4 41 14 433 43 0.3
10 7.7 5.3 79.3 27.5 15.8 11 0.0 140 N 5.7/2.2 1612 0.5/0.2 26 4 71 15 0.6
11 10.3 4.0 90.0 29.9 16.8 32 1.8 5 D-Dimer and PT: high 6.6/4.0 1899 1.3/0.7 78 22 262 48 0.8
12 11.5 7.0 84.7 26.4 17.0 37 3.2 30 PT, aPTT and D-Dimer: high 6.7/4.6 904 1.8/0.7 130 78 402 63 1.2
13 6.5 6.4 90.7 28.6 17.3 103 2.8 40 N 6.6/3.5 258 4.4/1.4 11 10 1097 26 0.5
14 9.1 12.6 87.9 30.0 14.6 48 0.8 10 ND 6.2/3.0 630 1.1/0.4 41 25 144 29 0.9
15 3.3 3.3 89.3 30.2 17.7 24 0.4 95 PT, aPTT and D-Dimer: high 5.4/2.6 777 1.8/1.6 43 18 82 161 1.6
16 16.2 8.7 92.1 30.3 17.8 23 ND 85 ND 5.9/2.3 708 3.3/1.6 41 18 156 114 2.3
17 37.1 6.6 80.5 26.2 21.7 76 3.6 94 PT and D-Dimer high, aPTT: N 7.3/3.3 1127 1.2/0.5 70 48 1225 23 1.0
18 37.4 8.5 91.8 28.9 16.0 18 2.2 30 PT, aPTT and D-Dimer: high 6.1/3.9 393 1.7/0.6 27 36 1507 17 0.5
19 17.1 8.4 91.0 31.5 16.9 54 4.2 47 PT high D-Dimer upper limit, 
aPTT:N
6.2/3.8 1290 0.7/0.3 68 75 638 37 0.5
*Normal ranges of serum chemical parameters: Total protein: 6.4–8.8 g/dl; Albumin3.0–5.5 g/dl; LDH: 190–380 U/l; Total bilirubin: 0.2–1.1 mg/dl; Direct bilirubin:0.0–0.4 mg/dl; AST: 0–40 U/L; ALT: 0–
43 U/L; ALP: 27–147 U/L; Urea: 15–50 mg/dl; Creatinine: 0.5–1.6 mg/dl; PT: prothrombin time; aPTT: active partial thromboplastin time; FDP: fibrin degradation products ND: not done; N: normalBMC Cancer 2005, 5:144 http://www.biomedcentral.com/1471-2407/5/144
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logical finding in this patient). Although biopsies have
some advantages, tumor cells occasionally can be seen in
aspirate preparations when biopsy sections are normal as
mentioned in literature, these two procedures should
therefore be regarded as complementary.
The management of a patient, whose solid malignancy is
disclosed from bone marrow, depends on his/her primary
tumor. The pathologist can assist the clinician by thor-
oughly examining the histologic specimen. In some cases
an immunoperoxidase staining for organ-specific antigen
examination might be sufficient to bring out of the pri-
mary focus. As an example, an immunoperoxidase stain
for prostatic acid phosphatase or prostate-specific antigen
may be helpful in establishing a diagnosis of metastatic
prostate cancer. On the opposite side of the spectrum in
some cases the pathologist could not comment on the pri-
mary site because of a poorly differentiated tumor. Maxi-
mum effort should be made to minimize the target. In
these tumors as a first step leukocyte common antigen
may be used to differentiate lymphohematopoietic neo-
plasm from other cancers. Patient # 7 and 10, who were
reported recently elsewhere separately [15,16], are good
examples for bringing out the primary focus by extra stain-
ings. The examination of patients with bone marrow
metastases of unknown origin should focus on detecting
treatable primary tumors [17]. This work up may result in
certain improvements in survivals of patients with pros-
tate carcinoma. Bone marrow metastases commonly arise
from lung, breast and prostate cancers; therefore, in case
of no clinical sign a reasonable work up should include a
chest roentgenogram, a prostate examination with serum
prostate specific acid phosphotase (PAP) in men; a breast
examination and mammography in women; computed
tomography scans also should be performed in suspected
cases. Serum tumor markers are not so useful in many
cases except PAP; considering their less specificity it is no
surprising. Because the expected survival of many patients
is quite short, laboratory and imaging studies should be
considered in view of their rationality.
Conclusion
In conclusion, MAHA, LEB and unexplained cytopenias
are strong indicators of the necessity of bone marrow
examination. Anemia, thrombocytopenia, elevated RDW
and hypoproteinemia form a uniform tetrad in patients
with disseminated tumors that are diagnosed via bone
marrow aspiration and biopsy. Because of the very short
survival of many patients, all investigational procedures
should be focused on treatable primary tumors.
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